Ralexar Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.ralexar.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Study in Subjects With Moderate Atopic Dermatitis
Phase 2
- Conditions
- Atopic Dermatitis Eczema
- Interventions
- Drug: ALX-101 Gel 5%Drug: ALX-101 Gel Vehicle
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Ralexar Therapeutics, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT03859986
- Locations
- 🇺🇸
Ralexar Investigational Site 10, Beverly Hills, California, United States
🇺🇸Ralexar Investigational Site 5, Los Angeles, California, United States
🇺🇸Ralexar Investigational Site 3, Aventura, Florida, United States
A Study in Subjects With Moderate Atopic Dermatitis
Phase 2
Completed
- Conditions
- Eczema, AtopicAtopic Dermatitis
- Interventions
- Drug: ALX-101 Gel 5% and ALX-101 Gel VehicleDrug: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Ralexar Therapeutics, Inc.
- Target Recruit Count
- 209
- Registration Number
- NCT03175354
- Locations
- 🇺🇸
Ralexar Investigational Site 35, Anniston, Alabama, United States
🇺🇸Ralexar Investigational Site 21, Birmingham, Alabama, United States
🇺🇸Ralexar Investigational Site 18, Laguna Hills, California, United States
News
No news found